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Analysis of hospital management of chronic respiratory diseases 
in light of the “Maps of Health Needs” project in Poland
Abstract
Introduction: The “Maps of Health Needs” project has been carried out in Poland since 2016 and its purpose is to implement 
quality-promoting and organisational solutions in the Polish healthcare system. This paper is the analysis of hospitalisations for 
chronic respiratory diseases recorded in Polish National Health Fund databases in 2014. 
Material and methods: The study included 122,000 hospitalisations of adults and 22,000 hospitalisations of children. Epidemio-
logical parameters (incidence and prevalence) and major hospitalisation parameters were determined through statistical analysis. 
Results: The highest registered incidence was observed in asthma patients (548 per 100,000 inhabitants) followed by COPD 
patients (233 per 100,000 inhabitants). Asthma patients were also characterised by the highest prevalence, with lower values 
being observed in COPD patients. In the group of adults, patients aged 65 years or older and 80 years or older accounted for 44% 
and 14% of hospitalised adults respectively. The analysis also revealed that 66% of hospitalisations of adults included patients 
with asthma, COPD and respiratory failure. The development of respiratory failure prolongs hospitalisation and increases both 
in-hospital and post-discharge mortality. In children, 90% of the identified hospitalisations were for asthma, chronic inflammatory 
lung diseases and cystic fibrosis. 
Conclusions: The results of the study demonstrate that pulmonary obstructive diseases are associated with a considerable 
burden. Therefore, corrective actions within the Polish healthcare system are required to decrease the number of hospitalisations 
for these diseases.
Key words: Maps of Health Needs, hospitalisations, chronic respiratory diseases
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Introduction 
According to the “European Lung White 
Book” 600,000 people die from respiratory diseas-
es in Europe each year, meaning that one in eight 
deaths is caused by them [1]. A total of 6 million 
hospitalisations due to respiratory diseases are 
recorded each year.
Epidemiological studies have shown that at 
least 1/3 of the population aged 5–80 years is at 
an increased risk of asthma, a lifetime risk for 
developing COPD in smokers is 40–50%, and lung 
cancer causes 20% of cancer-related deaths [1]. 
Until recently, cystic fibrosis (CF), a multi-organ 
genetic disease, was considered a childhood 
disease. Currently, however, as many as 42% of 
CF patients survive until the age of 18, and 5% 
— until 40 years of age. 
The “Maps of Health Needs” project (www.
mpz.mz.gov.pl/), co-financed by the European 
Social Fund (ESF) as part of the Operational Pro-
gramme Knowledge Education Development, is 
a project whose goals to implement quality-pro-
moting activities and organisational solutions in 
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the Polish healthcare system are in line with the 
trend of health promotion, in accordance with 
the Ottawa Charter [2].
The project resulted in the creation of a system 
for mapping health needs within 30 groups of dis-
eases and in the development of a base for systemic 
and implementation analyses within this scope. 
The aim of this study was to analyse hospi-
tal management of selected chronic respiratory 
diseases. 
Material and methods
Study population 
The study population comprised all patients 
in Poland in whom a hospitalisation was reported 
in 2014 due to the following diagnoses (ICD-10) 
being part of chronic respiratory diseases:
1. Asthma (J45, J46);
2. COPD (J43, J44);
3. Cystic fibrosis (CF) (E84);
4. Interstitial lung disease (ILD) (D86, J60–J67,
J70, J82, J84, J99);
5. Sleep-disordered breathing (SDB) (G47);
6. Chronic inflammatory lung diseases (J40–J42,
J47);
7. Respiratory failure (J96).
Patients treated in the drug programme were
excluded from the analysis of asthma. While an 
additional group of persons hospitalised for lung 
cancer was distinguished, it was not further ana-
lysed in detail since these patients often undergo 
diagnostic evaluation in respiratory wards, but in 
the Polish healthcare system they are treated in 
surgical and cancer wards.
Data collection 
The data used in this study were derived 
from the payment reconciliation database of the 
public payer in the Polish healthcare system 
[NFZ (Narodowy Fundusz Zdrowia) — National 
Health Fund]. In Poland, payments for healthcare 
services are settled by the NFZ in accordance 
with the principles of Diagnosis-Related Groups 
(DRGs). In cases of non-surgical treatment, clas-
sifications into appropriate groups are primarily 
based on the ICD-10 diagnosis. 
In addition to providing information about the 
diagnosis and the healthcare product paid for, the 
analysed database contained the following infor-
mation used to create aggregated data concerning 
individual diseases of the respiratory system:
—  Patient ID (enabling the same patient to be 
identified during different hospitalisations), 
including age, sex, and address;
—  Type and date of admission; type and date of 
hospital discharge;
—  Comorbidities;
—  Healthcare provider’s ID and geographical 
location;
—  Type of ward providing hospitalisation;
—  ICD-9 code procedure reported;
—  Post-discharge mortality rate, which was deter-
mined using the database of deaths by the Min-
istry of Internal Affairs and Administration.
Statistical analysis
Statistical analysis was conducted using R 
software, version 0.99.902, and was mainly based 
on the data.table package.
Epidemiological statistics included the 
 following parameters: 
—  Registered incidence — defined as the num-
ber of new patients with a specific diagnosis 
appearing in the public healthcare system. 
This parameter was calculated for 2014 on 
the basis of the NFZ data covering the period 
between 2009–2014;
—  Registered prevalence — defined as the num-
ber of individuals with a specific disease, 
estimated as from 31 December 2014. Indi-
viduals with a specific disease were defined 
as all patients classified as new cases of that 
specific disease in the public healthcare 
system since 2009, who were still alive on 
31 December 2014.
This publication also includes an analysis of 
hospitalisation-related parameters, such as:
—  Number of hospitalisations;
—  Cumulative percent of the number of hospi-
talisations;
—  Number of patients;
—  Number of hospitalisations per patient;
—  ALOS (average length of stay);
—  MLOS (median length of stay);
—  Number of patient-days of hospitalisation;
—  Average patient age;
—  Percentage of adult patients aged 65 years or 
older and aged 80 years or older (in the case 
of children, it is the percentage of children 
aged up to 1 year)
—  Percentage of in-hospital deaths;
—  30-day post-discharge mortality;
—  90-day post-discharge mortality.
Results 
The population analysed in detail consist-
ed of 122,000 adult patients [55,000 women 
and 67,000 men; mean age — 64 years; median 
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Table 1. Registered incidence and prevalence (2014)
  Registered incidence 
[thousand]
Registered incidence per 
100,000 inhabitants
Registered prevalence 
[thousand]
Registered prevalence 
per 100,000 inhabitants
Asthma 209 548 1854 4878
COPD 89 233 730 1920
ILD 19 51 136 357
SDB 20 53 122 320
Chronic inflammatory lung 
diseases
73 191 612 1611
Respiratory failure 22 56 61 161
COPD — chronic obstructive pulmonary disease; ILD — interstitial lung disease; SDB —  sleep-disordered breathing
age — 65 years; standard deviation (SD) — 15.3] 
and 22,000 children (aged up to 18 years; mean 
age — 6 years; median age — 5 years; SD — 4.6). 
The patients aged 65 years or older accounted for 
44% (63,000) of the analysed group, and those 
aged 80 years or older — 14% (20,000).
Nearly half of the hospitalised patients 
(48.6%) were in lung disease and tuberculosis 
wards. 
Incidence and prevalence 
The highest registered incidence values 
were observed in patients with asthma, and the 
lowest ones in individuals with respiratory failure 
(Table 1). The highest registered prevalence va-
lues were also observed in patients with asthma, 
 followed by patients with COPD and patients with 
chronic inflammatory lung diseases. 
Hospitalisations of adults 
The patients with COPD, respiratory failure 
and asthma accounted for 66% of the hospitali-
sations (Table 2). The subjects with COPD were 
characterised by the highest number of hospita-
lisations, the highest number of hospitalisations 
per patient (1.2) and the highest mean patient 
age, while as many as 29% of the hospitalised 
patients were those aged 85 years or older. The 
development of respiratory failure increased 
ALOS to 11.4 days.
The highest ALOS (12 days) was observed in 
the group of patients with CF, while the average 
number of hospitalisations per patient with CF 
was 2.2. This was the youngest and the smallest 
group among all hospitalised persons. 
Hospitalisations of children
The cumulative percent of the number of 
hospitalisations showed that the reason for ad-
mission to hospital was asthma, chronic inflam-
matory lung diseases and CF in 90% of the ho-
spitalised children (Table 3). The highest number 
of hospitalisations per patient was observed in 
patients with CF. The highest ALOS was found 
in patients with respiratory failure. 
Deaths in adults 
The development of respiratory failure led 
to 23% of in-hospital deaths, while 30% of the 
patients died within 30 days and 36% within 
90 days after hospital discharge (Table 4). In the 
case of COPD patients, in-hospital deaths consti-
tuted 3%, whereas 6% of the patients died within 
30 days and 10% within 90 days after hospital 
discharge (Table 4).
Deaths in children 
The development of respiratory failure in 
children was also associated with the highest 
in-hospital mortality (5%), while 7% and 9% of 
them died within 30 and 90 days after hospital 
discharge, respectively. With regard to CF pa-
tients, 1% of deaths within 30 days after hospital 
discharge was observed.
Discussion 
This publication discusses the burden of 
hospitalisations for chronic respiratory diseases 
on the Polish healthcare system. 
The analysed data concerned hospitalisations 
for which the diagnosis of chronic respiratory 
disease was the first to be reported with an ICD-
10 code.
It should, however, be emphasised that the 
method and order of ICD-10 coding may be the 
source of a reporting error [3] — an example can 
be the reporting of pneumonia in a patient with 
COPD using only one code. 
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Table 4. Analysis of deaths in adults
Adults Number 
of patients
Number of in- 
-hospital deaths
In-hospital deaths 
as a percentage  
of all deaths
30-day post-
-discharge
mortality
90-day post-
-discharge
mortality
Asthma (J45, J46) 24,586 146 1% 1% 2%
COPD (J43, J44) 35,957 1,304 3% 6% 10%
CF (E84) 381 8 1% 2% 4%
ILD (D86, J60–J67, J70, 
J82, J84, J99)
13,751 366 2% 4% 6%
SDB (G47) 15,243 2 0% 0% 0%
Chronic inflammatory lung 
diseases (J40–J42, J47)
13,340 115 1% 3% 5%
Respiratory failure (J96) 25,004 6,684 23% 30% 36%
CF — cystic fibrosis; COPD — chronic obstructive pulmonary disease; ILD — interstitial lung disease; SDB —  sleep-disordered breathing
The highest registered incidence was ob-
served in patients with asthma, followed by sub-
jects with COPD. Patients suffering from asthma 
were also characterised by the highest prevalence, 
while lower values were observed in individuals 
with COPD. 
The cumulative percent of the number of 
hospitalisations showed that asthma, COPD and 
respiratory failure were responsible for 66% of 
hospitalisations of adults. The highest number of 
adult patients was hospitalised for COPD. Regard-
less of the underlying disease, the development 
of respiratory failure leads to the deterioration of 
the prognosis, prolongation of hospitalisation and 
increase in both in-hospital and post-discharge 
mortality. 
Asthma, chronic inflammatory lung diseases 
and CF accounted for 90% of children’s hospital-
isations. Asthma was the reason for the highest 
number of hospitalisations. In children with CF, 
there was a relatively lower number of hospital-
isations per patient. Respiratory failure prolonged 
the length of hospital stay significantly and was 
associated with higher mortality. 
Respiratory system diseases are a complex, 
medical and economic problem in every country 
[1, 4–6]. The analysis of respiratory diseases, 
conducted in the United Kingdom, demonstrated 
that 12.7 million British individuals had a history 
of asthma, COPD or another chronic respiratory 
disease [6]. It is widely accepted that 50% of 
deaths and 25% of hospitalisations are caused by 
tobacco-related diseases, including lung cancer 
or COPD. 
In 2011, a total of 694,000 hospitalisations 
were reported, 8% of which were for diseases of 
the respiratory system. Respiratory system diseas-
es were the reason for 703,116 (8.3%) of hospital-
isations, which translated into 6,167,509 patient 
days (10%). 
The authors of the publication noted that the 
patient age significantly affected the percentage 
of hospitalisations in relation to a given diagno-
sis. Therefore, in children aged up to 14 years, 
23.4% of the hospitalisations resulted from con-
genital anomalies and respiratory complications 
associated with them — 18% were for asthma and 
1.9% were for CF.
At ages 15–64 years, asthma accounted for 
15.5% of the hospitalisations, COPD — 18.2%, CF 
— 3.1%, and lung cancer — 7.1%. In patients aged 
65 years or older, asthma accounted for as little 
as 2.2% of the hospitalisations, COPD — 26.5%, 
and lung cancer — 7.8%. 
The number of hospitalisations for COPD was 
43,134, which corresponded to 350,512 patient 
days, while ALOS was 8.1 days. In the UK anal-
ysis, there were 204,798 hospitalisations (2.4%), 
which corresponded to 2,346,324 (3.8%) patient 
days [6].
Many foreign analyses point to the burden of 
hospitalisations for COPD on healthcare systems 
even though incidence and hospital morbidity 
rates vary considerably. For instance, Oceania 
and, particularly, Australia and New Zealand, 
have a more considerable burden of hospitalisa-
tion than Poland [7, 8].
In New Zealand, the burden of hospital-
isations for COPD varies by region and ranges 
from 410 per 100,000 inhabitants to 1,144 per 
100,000 inhabitants [7].
In 2010, prevalence in Australia constituted 
317 hospitalisations per 100,000 inhabitants [8].
In the Australian and New Zealand statistics 
alike, there was a significant impact of socio-
economic status on hospital morbidity, longer 
Advances in Respiratory Medicine 2020, vol. 88, no. 4, pages 1–8
6 www.journals.viamedica.pl
hospitalisations and more frequent hospital re-
admissions [7, 8].
It should be emphasised that patients aged 
65 years or older are a significant burden on hos-
pitals. This paper reveals that the percentage of 
patients aged 65 years or older as well as patients 
reaching 80 years or older accounted for 86% and 
29%, respectively.
In addition, this study showed that hos-
pitalisations for COPD translated into 3% of 
in-hospital deaths, 6% of deaths within 30 days 
and 10% of deaths within 90 days after hospital 
discharge. The development of respiratory failure 
increases these percentages to 23%, 30% and 36%, 
respectively. 
The issue of increased mortality after acute 
exacerbations of COPD was already considered 
several years ago [9–11]. A previous acute exac-
erbation requiring hospitalisation is known to be 
a significant risk factor for hospital readmission, 
whereas the risk of death increases seven-fold 
[11]. The study by Groenwegen et al. found 
that 8% of acute exacerbations of COPD led to 
in-hospital deaths and 23% of such patients died 
within one year after hospital discharge [9]. Re-
spiratory failure leading to hospitalisation in an 
intensive care unit increases the death rate within 
one year after hospital discharge to 35%. The risk 
factors include: treatment with oral corticostero-
ids; hypercapnia; old age.
Even though a Danish study conducted be-
tween 2002–2008 demonstrated the reduction 
of the annual hospitalisation rate from 460 per 
100,000 inhabitants in 2002 to 410 per 100,000 in-
habitants in 2008 [10], the increase in in-hospital 
mortality [odds ratio (OR) — 1.16] and increased 
post-discharge mortality rate within one year 
(OR — 1.12) were also observed. Increased morta-
lity was primarily found in patients with respira-
tory failure and multiple comorbidities; however, 
the distance to the hospital and treatment with 
oral corticosteroids — as in the case of the study 
by Groenwegen et al. — were also of relevance 
there. Bed occupancy also contributed to the 
adverse outcome of treatment. It was found that 
the decrease in the number of hospitals and beds 
resulted in the centralisation of hospitalisations 
for more severe cases of the disease. In the authors’ 
opinion, this organisational change improved the 
prehospital care of patients with COPD.
The decrease in hospitalisations by 14% was 
also noted after a smoking ban had been introdu-
ced in Spain [12].
In 2014, a total of 46,000 hospitalisations 
for asthma were reported in Poland, including 
29,000 of hospitalised adults and 17,600 of hos-
pitalised children. Hospital morbidity rates con-
stituted 92 per 100,000 inhabitants in adults and 
253 per 100,000 inhabitants in children. In adults, 
the majority of the hospitalisations (18,000) were 
in lung disease and tuberculosis wards, followed 
by internal medicine wards (7,500) and allergy 
wards (3,500). The median lengths of stay varied 
by province and ranged from 3 to 6 days. Five 
percent of adult patients with asthma were hos-
pitalised for more than 14 days. Acute severe 
asthma (status asthmaticus) (J46) was reported 
in the patients with asthma and ranged from 1% 
in the Kuyavian-Pomeranian Voivodeship to 13% 
in the Łódź Voivodeship.
This analysis merely shows the burden of 
asthma on the Polish healthcare system, which 
has been revealed by reporting activities, and 
may contain some errors due to incorrect diag-
nosis and incorrect reporting of an obstructive 
respiratory disease (asthma, COPD or coexis-
tence of both). It is also important to differen-
tiate between a hospitalisation for diagnostic 
evaluation of a disease and an acute exacerba-
tion requiring hospitalisation. The unavailabil-
ity of specialist outpatient care in the patients’ 
local health centres often leads to unnecessary 
hospitalisations. 
It should be noted that the number of patients 
registered in the NFZ databases has been relative-
ly constant since 2009, with a predominance of 
women (115%) [13]. Approximately 55–57% of 
the registered patients live in urban areas, and 
43–45% live in rural areas.
The GINA (Global Initiative for Asthma) 
document provides extensive information that 
suggests the possibility of controlling the dis-
ease outside the hospital setting (GINA) [5]. It is 
believed that the number of hospitalisations for 
asthma is proportionate to decreased disease con-
trol [14]. A considerable number of factors affects 
asthma control, including as follows: the lack of 
a correct diagnosis, undertreatment, patients’ 
non-compliance, the lack of or non-adherence to 
a treatment plan. 
In Australia, for instance, a 10% reduction in 
the number of hospitalisations was observed in 
2015 when compared to 2010. In 2015, hospital 
morbidity averaged 1.85 per 1,000 inhabitants 
(1.93 per 1,000 inhabitants in urban areas and 
1.64 per 1,000 inhabitants in rural areas). The 
authors point out to the fact that in epidemio-
logical studies, optimisation of asthma treatment 
requires taking age, sex and place of residence 
under consideration. They stress the role of 
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primary care regarding the coordinated care of 
patients with asthma. 
In Portugal, hospitalisations for asthma ac-
counted for 2.5 per 1,000 hospitalisations, 28.1 per 
100,000 inhabitants (66.6 per 100,000 individuals 
aged below 19 years) [16]. In-hospital deaths were 
estimated at 8 per 1,000 hospitalisations, corre-
sponding to 2.4 per 1,000,000 inhabitants. Mor-
tality statistics remain unchanged. 
Hospitalisations of children with asthma 
merit a separate discussion. The diagnosis of 
asthma is more difficult to make in a child than 
in an adult for various reasons, which include 
the multiplicity of non-specific symptoms in the 
former. Many asthma phenotypes, including the 
wheezing phenotype, are particularly difficult 
to differentiate from asthma in this group of 
patients. Wheezing is a common symptom (espe-
cially in younger children) of many respiratory 
diseases, which causes that it is particularly diffi-
cult to differentiate it from asthma. It is often the 
case that children are hospitalised for bronchitis 
or bronchiolitis (the so-called wheezing babies), 
which is subsequently coded as asthma. 
To sum up, the problem of hospitalisation for 
asthma in Poland includes:
—  Conditions of the healthcare system;
—  No asthma control, resulting from the lack of 
insufficient diagnosis and undertreatment of 
the disease; 
—  Differences in the diagnosis and treatment of 
asthma in children; 
—  Incorrect diagnosis (the lack of differentiation 
of asthma from COPD); 
—  A high proportion of smokers;
—  Disease coding and reporting to the NFZ;
—  Differences in coverage of medicines intend-
ed for the treatment of obstructive pulmonary 
diseases.
It is also important to consider statistical 
differences depending on the country in which 
the analysis is conducted: in Norway, the number 
of hospitalisations of children decreased by 51%, 
while it remained unchanged in Sweden [17]. 
According to the “European Lung White 
Book,” the prevalence of asthma is estimated at 
1.6–20% in Europe, whereas 60% of patients with 
allergies are mainly allergic to animal hair, dust 
and mould, including 10–20% of them have the 
wheezing phenotype that is difficult to differen-
tiate [1].
Due to the complex clinical presentation of 
CF and multidirectional treatment, the quality 
of care provided to CF patients, as measured by 
lifespan, is considered one of the best indicators 
of healthcare quality in developed countries 
[18–20].
The most recent US studies have revealed 
that life expectancy of people born in 2010 is 
40 years for females and 37 years for males [18].
In Poland, average lifespan of CF patients 
is shorter than that in Western Europe and the 
United States. Cystic fibrosis, a disease once con-
sidered a childhood one, currently affects adults 
as well (who only account for approx. 1/3 of all 
CF patients). Patients with CF account for 1% of 
hospitalisations of adults (with the mean age of 
25 years) and 8% of hospitalisations of children 
(with the mean age of 8 years).
It is thus justified to follow the example of 
the rest of Europe by making attempts to establish 
CF treatment centres and to provide CF patients 
with comprehensive and multidisciplinary care. 
Hospitalisations for CF occur at any age and 
the main reason is deterioration of lung function 
[20]. The most common management strategy 
involves intravenous antibiotic therapy, clean-
sing of the respiratory tract through appropriate 
inhalation and drainage therapy combined with 
an appropriate diet. Pulmonary rehabilitation 
is the key to the beneficial outcome of hospita-
lisation. 
The registry of CF patients in the United Sta-
tes included 21,488 patients in 2003 and 28,134 in 
2013, as well as collected data on hospitalisa-
tions [18]. The number of hospitalisations per 
1,000 CF patients increased from 994 to 1,072 in 
2013. During hospitalisation, 1.5% of the patients 
aged 27 years on average died (MLOS — 7 days). 
Between 2003 and 2013, mortality decreased from 
1.9% to 1.2%. The risk factors included: chronic 
liver disease, acute kidney disease, and previous 
lung transplantation (6.5% of the hospitalisa-
tions). Keeping registries of CF patients contri-
butes to improved patient care and to the pursuit 
of novel — often individualised — treatments. 
Conclusions
This publication serves as evidence that ho-
spitalisations for asthma and COPD, especially 
those complicated by respiratory failure, consti-
tute a serious burden on the Polish healthcare sys-
tem. In accordance with the project assumptions, 
organisational and implementation-related ac-
tions have to be taken to reduce this burden. 
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